Overview
The VKORC1 gene encodes the rate-limiting enzyme of the hepatic vitamin K cycle. Without active reduced vitamin K, the liver cannot carboxylate key blood-clotting factors (II, VII, IX, and X) as well as matrix Gla proteins protecting arterial walls from calcification.
VKORC1 is also the direct pharmacological target of oral vitamin K antagonists such as warfarin (Coumadin) and phenprocoumon, making it alongside CYP2C9 one of the most validated dosing markers in coagulation genetics.
16p11.2 (Chromosome 16)
Detoxification & Coagulation
Vitamin K Recycling Enzyme
Warfarin / coumarin sensitivity
Function of VKORC1
Warfarin inhibits VKORC1 to thin blood selectively. Because the promoter SNP rs9923231 changes how much VKORC1 enzyme liver cells synthesize in the first place, starting doses vary dramatically from person to person.
Key Aspects:
📉 Sensitive Phenotype (-1639 A/A)
Lower baseline VKORC1 levels mean even modest warfarin doses block most of the available enzyme, raising INR rapidly and requiring low initial doses.
📈 Higher Requirement (-1639 G/G)
Full hepatic enzyme production provides greater buffering capacity, generally calling for higher average maintenance doses to stay within target INR.
🧬 Genetic Variants (SNPs)
Two regulatory SNPs in VKORC1 explain the majority of inherited coumarin dose variability worldwide:
16:31096368
Reduces promoter transcription activity; A/A carriers typically need ~40-60% lower warfarin maintenance doses than G/G individuals.
~40% (Europe), ~90% (East Asia)
16:31091000
Marks haplotypes associated with relatively higher coumarin dose requirements and lower bleeding tendency during induction.
~35% (Europe)
Practical Significance
✅ Strategies & Guidance
- INR Monitoring During Initiation: Close INR tracking prevents supratherapeutic over-anticoagulation in the first two weeks.
- Consistent Vitamin K Intake: Keep daily intake of leafy greens (spinach, kale, broccoli) steady rather than eliminating them completely.
- Medication Card Documentation: Share known VKORC1 and CYP2C9 genotypes with anticoagulation clinics prior to starting warfarin.
⚠️ Clinical Notes & Risks
- Major Bleeding Risk: Standard loading doses in A/A or compound VKORC1/CYP2C9 carriers may overshoot target INR quickly.
- Subtherapeutic Dosing: Abrupt high-dose vitamin K supplements can antagonize therapy acutely.
- Note on DOACs: Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) act independently of VKORC1.
📚 Data Sources
- OMIM: #608547 (Vitamin K Epoxide Reductase Complex, Subunit 1)
- dbSNP: rs9923231 (-1639G>A), rs7294
- CPIC Guideline: Pharmacogenetics-Guided Warfarin Dosing
- ClinVar: VKORC1 Warfarin Sensitivity Clinical Annotations
Last Update: November 2026
Related Research Guides for VKORC1
Related Genes in Detoxification
GSTP1
GSTP1 is an important detoxification enzyme that neutralizes toxins and drugs by binding them to glutathione....
NAT2
NAT2 drives Phase II liver acetylation of drugs (isoniazid, sulfonamides) and heterocyclic amines. Variants divide individuals…
SLCO1B1
SLCO1B1 (OATP1B1) imports statin cholesterol drugs and bilirubin from blood into liver cells. The *5 variant…